NICE has issued draft guidance recommending against NHS reimbursement of Sanofi's Zaltrap (aflibercept) for treating patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsNewTreatmentColorectalCancer.jsp